Key Points
- Ultragenyx Pharmaceutical director Corazon (Corsee) Sanders sold 2,000 shares on June 15 at an average price of $25.05, totaling $50,100. After the transaction, Sanders still held 21,095 shares.
- RARE shares rose 4.2% and opened at $25.38, with the stock trading near its 50-day and 200-day moving averages. The company has a market cap of about $2.5 billion.
- The company recently missed quarterly earnings expectations, reporting an EPS loss of $1.84 versus the expected $1.49 loss and revenue of $136 million versus the $158.19 million estimate. Analysts currently rate the stock a Moderate Buy with a consensus price target of $59.56.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares of the company's stock, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ultragenyx Pharmaceutical Stock Up 4.2%
Shares of RARE opened at $25.38 on Tuesday. The company has a 50-day simple moving average of $24.04 and a 200-day simple moving average of $25.02. The company has a market capitalization of $2.50 billion, a PE ratio of -4.15 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analysts' expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business's revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.57) EPS. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
A number of large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC grew its stake in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,440 shares during the last quarter. Amundi acquired a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $318,000. EverSource Wealth Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 573.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 1,845 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Ultragenyx Pharmaceutical by 25.6% during the 1st quarter. California State Teachers Retirement System now owns 104,650 shares of the biopharmaceutical company's stock worth $2,192,000 after purchasing an additional 21,313 shares during the last quarter. Finally, Eagle Health Investments LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $18,522,000. 97.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the stock. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 6th. Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 29th. Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an "overweight" rating in a research note on Thursday, April 16th. Guggenheim lowered their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a "buy" rating on the stock in a research note on Friday, May 8th. Finally, HC Wainwright lowered their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $59.56.
View Our Latest Analysis on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
